Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Johnson & Johnson (JNJ) shares

Learn how to easily invest in Johnson & Johnson shares.

Johnson & Johnson (JNJ) is a leading drug manufacturers-general business based in the US. It opened the day at USD$157.91 after a previous close of USD$157.09. During the day the price has varied from a low of USD$157.59 to a high of USD$159.67. The latest price was USD$159.38 (25 minute delay). Johnson & Johnson is listed on the NYSE and employs 134,500 staff. All prices are listed in US Dollars.

How to buy shares in Johnson & Johnson

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – JNJ – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online trading platforms

Name Product Number of Stocks CFDs Shares Available Markets
eToro
2,000+
Yes
Yes
Worldwide with exception.
CFD Service. Your capital is at risk.
Get commission-free US stock trading plus access to forex, cryptocurrencies, ETFs, and commodities with the world’s leading social trading and investment platform.
Plus500
2,000+
Yes
No
Worldwide with exception.
CFD Service. Your capital is at risk.
Trade over 2,500 financial instruments with one of the largest CFD providers in the world.
Prime XBT
Access to global markets
No
Yes
US, IN, ES, JP, AU, UK, CN, DE, CA, CH, MX, NZ, CH, HK, FR
CFD Service. Your capital is at risk.
Trade cryptocurrencies and traditional financial instruments such as commodities, indices, and forex across 50+ markets.
Zacks Trade
Access to global markets
No
Yes
US, CA, MX, AUT, BEL, FR, DE, IT, NL, ES, NO, SE, UK, CH, HK, JP, SG, RU, AU
CFD Service. Your capital is at risk.
Trade stocks, bonds, ETFs, options, and more on 90+ international exchanges. Offers customizable trading platforms with over 120 technical indicators for your charting needs.
Eightcap
Access to global markets
Yes
No
UK, DE, AU
CFD Service. Your capital is at risk.
Trade a wide variety of instruments on the award-winning MT4/5 platforms with this Australia-based CFD and forex broker.
Firstrade
Access to US stocks
No
Yes
US
CFD Service. Your capital is at risk.
Enjoy $0 commission trading for stocks, options, funds, and more with this internationally-acclaimed discount broker.
CM Trading
N/A
Yes
No
US, FR, DE, UK, AU, ZA, CH. HK, JP, ES, NL, IT
CFD Service. Your capital is at risk.
Licensed international brokerage and CFD provider that offers advanced trading solutions designed for both new and experienced traders alike.
Exness
N/A
Yes
No
CH, VN, TH, PH, SG, ID, IN, UAE, ZA, SA, EG, BR, CR, MX
CFD Service. Your capital is at risk.
Enjoy fast trade executions at competitive fees with this award-winning retail forex broker.
Interactive Brokers
Access to global markets
No
Yes
US, MX, RU, ES, UK, DE, IL, HK, SG, IN, KR, AU, CH, HU, CA
CFD Service. Your capital is at risk.
Take advantage of low trading fees, multiple platform support, and an extensive list of asset classes across global markets, including stocks, options, futures, forex, bonds, and funds.
loading

Compare up to 4 providers

How has Coronavirus impacted Johnson & Johnson's stock price?

Since the stock market crash in March caused by coronavirus, Johnson & Johnson's stock price has had significant positive movement.

Its last market close was $159.38, which is 5.93% up on its pre-crash value of $149.93 and 46.01% up on the lowest point reached during the March crash when the stocks fell as low as $109.16.

If you had bought $1,000 worth of Johnson & Johnson stocks at the start of February 2020, those stocks would have been worth $740.19 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,061.47.

Is it a good time to buy Johnson & Johnson stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Johnson & Johnson shares at a glance

Information last updated 2021-12-03.
Open$157.91
High$159.67
Low$157.59
Close$159.38
Previous close$157.09
Change $2.29
Change % 1.4578%
Volume 8,488,028
Information last updated 2021-12-04.
52-week range$144.86 - $177.77
50-day moving average $161.89
200-day moving average $165.59
Wall St. target price$187.76
PE ratio 23.8201
Dividend yield $4.14 (2.64%)
Earnings per share (TTM) $6.69

Johnson & Johnson stock price (NYSE: JNJ)

Use our graph to track the performance of JNJ stocks over time.

Johnson & Johnson price performance over time

Historical closes compared with the close of $159.38 from 2021-12-03

1 week (2021-11-26) 0.11%
1 month (2021-11-05) -2.48%
3 months (2021-09-03) -8.95%
6 months (2021-06-04) -3.97%
1 year (2020-12-04) 6.06%
2 years (2019-12-05) 14.20%
3 years (2018-12-04) 9.14%
5 years (2016-12-05) 42.38%

Is Johnson & Johnson under- or over-valued?

Valuing Johnson & Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson & Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Johnson & Johnson's P/E ratio

Johnson & Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Johnson & Johnson shares trade at around 24x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Johnson & Johnson's PEG ratio

Johnson & Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5396. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson & Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Johnson & Johnson's EBITDA

Johnson & Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $31.5 billion.

The EBITDA is a measure of a Johnson & Johnson's overall financial performance and is widely used to measure a its profitability.

Johnson & Johnson financials

Revenue TTM $91.4 billion
Operating margin TTM 26.29%
Gross profit TTM $54.3 billion
Return on assets TTM 8.59%
Return on equity TTM 26.54%
Profit margin 19.55%
Book value $26.69
Market capitalisation $413.6 billion

TTM: trailing 12 months

Johnson & Johnson's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson & Johnson.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Johnson & Johnson's total ESG risk score

Total ESG risk: 35.8

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson & Johnson's overall score of 35.8 (as at 12/31/2018) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Johnson & Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Johnson & Johnson's environmental score

Environmental score: 3.79/100

Johnson & Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson & Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Johnson & Johnson's social score

Social score: 25.14/100

Johnson & Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson & Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Johnson & Johnson's governance score

Governance score: 14.87/100

Johnson & Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson & Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Johnson & Johnson's controversy score

Controversy score: 4/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson & Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson & Johnson has a damaged public profile.

Johnson & Johnson share dividends

44%

Dividend payout ratio: 43.97% of net profits

Recently Johnson & Johnson has paid out, on average, around 43.97% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.7% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson & Johnson shareholders could enjoy a 2.7% return on their shares, in the form of dividend payments. In Johnson & Johnson's case, that would currently equate to about $4.14 per share.

While Johnson & Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson & Johnson may be investing much of the rest of its net profits in future growth.

Johnson & Johnson's most recent dividend payout was on 6 December 2021. The latest dividend was paid out to all shareholders who bought their shares by 21 November 2021 (the "ex-dividend date").

Have Johnson & Johnson's shares ever split?

Johnson & Johnson's shares were split on a 2:1 basis on 12 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson & Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson & Johnson shares which in turn could have impacted Johnson & Johnson's share price.

Johnson & Johnson share price volatility

Over the last 12 months, Johnson & Johnson's shares have ranged in value from as little as $144.8593 up to $177.7656. A popular way to gauge a stock's volatility is its "beta".

JNJ.US volatility(beta: 0.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson & Johnson's is 0.7013. This would suggest that Johnson & Johnson's shares are less volatile than average (for this exchange).

Johnson & Johnson overview

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o. b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand.

Shares similar to Johnson & Johnson

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site